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Abstract  
Introduction 
Assessing the fidelity of complex behavioural interventions and examining the contextual rea-
sons why such interventions succeed, or fail are important activities but challenging and rarely 
reported. The Smoking Treatment Optimisation in Pharmacies (STOP) trial is a cluster ran-
domised trial evaluating the effectiveness of a complex intervention to optimise the National 
Health Service (NHS) Stop Smoking Service delivered in community pharmacies. This com-
plex intervention comprises a training package for pharmacy staff involving motivational inter-
viewing and communication skills aimed at increasing smoking cessation knowledge and pro-
active client engagement. We report on a process evaluation which was planned alongside 
the trial to offer findings that will assist in the interpretation of the main trial results and help 
inform potential implementation in community pharmacy settings on a wider scale. 
Methods and analysis  
Quantitative data on recruitment and retention process of pharmacies, pharmacy staff and 
service users has been collected during the trial along with data on dose and fidelity of the 
intervention delivery from participating intervention arm pharmacies to identify potential imple-
mentation issues. Simulated client data on behaviour change skills and display of intervention 
materials from both control and intervention pharmacies is being assessed. These data will 
be combined with qualitative data; including adviser-smoker consultation recordings that pro-
vide a snapshot of behaviour skills delivery by stop smoking advisers and semi-structured 
interviews with pharmacy staff and services users from the intervention arm. 
Discussion  
Published protocols for process evaluations of complex health interventions are still rare de-
spite increasing funding for this work to facilitate understanding of trial outcomes from an im-
plementation perspective. This mixed methods protocol will contribute to the developing liter-
ature around the conduct of process evaluation and the value they add to health services 
research. 
 
Trial registration number ISRCTN16351033. 
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Strengths and limitations of this study 
• A planned mixed methods process evaluation that draws together data from different 
sources to help explain the trial results and establish the feasibility of scaling this complex 
intervention up in community pharmacy settings. 
• A strength is the use of a previously tested mystery shopping method to assess fidelity of 
skills performance at the pharmacy counter 
• The process evaluation relies on willing pharmacy staff and service users involved in the 
trial to collect some of the data, which may introduce bias. 
• This paper also provides a detailed example of how to use the MRC framework for process 
evaluation of complex interventions to design an extensive process evaluation within trial 
settings.  
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Introduction  
 
The Smoking Treatment Optimisation in Pharmacies (STOP) trial is a cluster randomised trial 
to evaluate the effectiveness of a complex intervention to optimise the NHS Stop Smoking 
Service delivered in community pharmacies [1]. The trial involves 60 pharmacies across Lon-
don, Coventry and Cwm Taf in Wales. Thirty of these pharmacies are randomised to the in-
tervention group, where consenting pharmacy staff are invited to a half-day session which 
includes motivational interviewing and communication skills training to improve smoker en-
gagement and equip them as facilitators for health behaviour change [2, 3]. Intervention phar-
macies are also given badges, a poster and a desk calendar to use in their pharmacy envi-
ronment as prompts for more proactive smoking cessation dialogue with potential clients. The 
control pharmacies continue to deliver their service as normal over the trial duration. The pri-
mary outcome is rate of smoker recruitment into the NHS stop smoking service [1]. The trial, 
along with this process evaluation, was funded the NIHR Programme Grant for Applied Re-
search [RP-PG-0609-10181]. In this paper we describe the protocol for a process evaluation 
which aims to evaluate how the intervention is implemented, the mechanisms by which it 
works and how these may be affected by the context in which the intervention is operating [4].  
 
Process evaluations can be used to assess the fidelity and quality of implementation of an 
intervention, clarify causal mechanisms and identify contextual factors associated with varia-
tion in outcomes [4]. They are recommended to contextualise the results of randomised con-
trolled trials to answer key questions about why an intervention has failed or succeeded and 
how it was implemented [5]. Process evaluations are particularly relevant to complex, multi-
faceted interventions such as STOP that involve multiple targets (for example, pharmacy staff 
and patients/ service users), have various active components and where their complexity 
makes it difficult to measure their effects [2, 6].   
 
In our previous STOP qualitative and pilot studies, stop smoking advisers felt they lacked the 
interpersonal skills necessary to engage well with smokers and help them to quit [7]. Advisers 
suggested regular skills training for all pharmacy staff, including staff not formally trained as 
stop smoking advisers, to improve uptake to their stop smoking service [2-3, 7-8]. Despite 
expanding the intervention training to include staff members that were not directly involved in 
delivering the pharmacy smoking cessation service in the main trial, we noticed a high level 
of staff turnover in a majority of participating trial pharmacies which may affect the reach/im-
plementation of the intervention. Specifically, even if high levels of attendance to the interven-
tion training are achieved, the effectiveness of the behavioural aspect of the intervention may 
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be constrained/ diluted over time if many intervention trained staff leave the pharmacy for 
whatever reason.  
 
Variations in organisational structures of pharmacies and commissioning systems also caused 
complications in the process of the trial. We noted that the routes to receiving payment (e.g. 
smoker registration vs 4 week quit outcome) and payments offered (total amount received per 
smoker plus bonus for specific groups) for pharmacies providing the NHS Stop Smoking Ser-
vice differed in London, Coventry and Wales depending on each service commissioner’s pol-
icy [9]. These differences also extend into data collection where the type of routine data that 
is collected in each geographical location varied because of the different computer systems 
used. London and Coventry for example both used electronic portals to track and upload 
claims and patient data, but did not collect the exact same data fields. On the other extreme 
Wales relied more heavily on paper records which the STOP team used to collect and manu-
ally transcribe onto an electronic spreadsheet. 
  
The above challenges highlighted a need to conduct a pragmatic process evaluation that al-
lows us to understand better the contextual factors and causal mechanisms in community 
pharmacy settings that could affect implementation of the STOP intervention during the trial 
and subsequent trial outcomes. The process evaluation will support quantitative data collected 
from the 60 participating pharmacies across three regions – London, Coventry and Cwm Taf. 
The evaluation will enable us to place the pharmacies in context, assess fidelity of the inter-
vention, quantify the intervention dose delivered, the intervention dose received and the extent 
to which the target population participated in the intervention (including recruitment rates for 
pharmacies, staff and smokers). 
 
The design of the process evaluation is underpinned by the Medical Research Council guid-
ance [4] and the theoretical framework used to develop the STOP intervention [2, 3]. Specifi-
cally, development of this protocol is based on the key components of process evaluation 
proposed by Moore and colleagues [4] which are: context, reach, dose delivered, dose re-
ceived, fidelity, implementation and recruitment [10]. From a theoretical perspective, outputs 
from the activities outlined in the final STOP logic model (Figure 1) alongside the STOP pro-
gramme theories will be used to identify the causal processes through which change comes 
about as a result of a programme's strategies and action [11]. In addition, we decided that it 
was important to include the views and opinions of participants, including pharmacy staff who 
attended the STOP intervention training and consenting STOP Trial service users, who used 
the stop smoking service at participating pharmacies. Their experiences, their attitudes to the 
intervention and how they think the intervention could be improved will play an important part 
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in interpreting the outcome data and developing subsequent implementation. This process 
evaluation protocol establishes how we will evaluate the fidelity of implementation of the STOP 
intervention, clarify causal mechanisms and identify factors associated with variation in the 
STOP Trial outcomes [1]. 
 
The specific process evaluation aims for the STOP Trial are;   
1. To provide findings that will assist in the interpretation of the clinical trial results, particularly 
understanding how and in what circumstances the STOP Intervention improves smoker 
uptake (or not)  
2. To inform potential implementation of the STOP training intervention in community phar-
macy settings on a wider scale  
 
Methods  
Design 
This process evaluation will use quantitative and qualitative data. The use of mixed methods 
research is increasingly common in health services research and evaluation [12]. Specific to 
process evaluations, a mixed method approach can help researchers to explore apparent dis-
crepancies between findings [12-13]. There are practicalities to this methodological approach 
that require careful forward planning including how each method will complement the other, 
and which data collection methods to use to achieve the project's goals [13]. Quantitative data 
(e.g. intervention dosage, pharmacy staff client engagement scores from simulated clients; 
facilitator training adherence scores) will be complemented by qualitative data from pharmacy 
staff and service user interviews, intervention training attendees’ feedback, plus field notes 
from pharmacy booster visits and simulated client visits to illuminate why the intervention was 
effective or not [3, 13].  
 
Process evaluation objectives  
Ø Collect quantitative data on number of pharmacies recruited, and pharmacy staff con-
sented to the STOP Trial, records of pharmacy staff trained in informed consent in 
research and trial related processes during site initiation visits. Include reported num-
bers of staff employed by participating pharmacies to assess reach 
Ø Collect quantitative data on the proportion of pharmacy staff invited and attending train-
ing with reasons for non-attendance from the intervention arm. Data on training venues 
will also be collected 
Ø Collate and analyse quantitative data from simulated clients regarding display of inter-
vention materials and client engagement by pharmacy staff at the counter. This data 
will also include field notes to be analysed qualitatively 
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Ø Analyse audio recordings of STOP training sessions to assess fidelity of intervention 
delivery by training facilitators  
Ø Assess acceptability of the STOP intervention by interviewing pharmacy staff about 
their views of the STOP training, and perceived impact of the intervention on their NHS 
stop smoking service. These interviews will be transcribed, then later analysed quali-
tatively alongside pharmacy staff post training feedback data collected after each train-
ing session and 5 months later. 
Ø Collate data on service user satisfaction of the NHS SSS from the NCSCT question-
naire 
Ø Carry out interviews with consenting service users on their views of the stop smoking 
service from participating pharmacies 
Ø Collate data on number of booster visits conducted in intervention pharmacies, and 
analyse field notes, describing contextual factors reported by pharmacy staff that hin-
dered or facilitated implementation of the STOP intervention in their environment 
Ø Interpret key outputs and results to provide informative descriptive reports and statis-
tical analyses 
Ø Disseminate comprehensive process evaluation outcomes report through peer re-
viewed articles, and presentations at academic conferences and stakeholder events 
 
Figure 2 provides a summary of key process evaluation components in accordance with MRC 
guidance, associated theoretical assumptions (see Figure 1), and how these will be measured 
within data collected.   
 
Data Collection Methods 
 
Table 1 outlines the methods used to collect specific STOP Trial data for this process evalu-
ation.   
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Fidelity assessment will be conducted in three ways:  
1. Audio-recordings of STOP pharmacy staff training sessions  
2. Assessment of prompts and client engagement with staff at the pharmacy counter us-
ing simulated clients  
3. Audio-recordings of advisor-smoker consultations  
 
Audio-recordings of STOP pharmacy staff training sessions  
Audio-recordings of training sessions will only be obtained if the group provides verbal consent 
to be recorded. Specifically, before starting each training session, the training facilitators (or 
study team) will ask attendees being trained if they are happy for their session to be recorded. 
Facilitators will explain the reason for this i.e. to assess adherence to intervention content 
being delivered according to the STOP intervention training manual. Content in this training 
manual has been previously coded into component behaviour change techniques (BCTs) by 
two health psychologists from the study team (see table 2) with previous training and experi-
ence in coding using the BCT taxonomy [2, 3].  
 
Two qualitative researchers (independent from the study team) will independently listen to 
each recording and rate (coded as 0 (NO) or 1 (YES) whether the facilitator applied all speci-
fied BCTs outlined in the manual,[14] and learnt during the training in practice. They will then 
subsequently meet to review their ratings and resolve any discrepancies along with the pro-
cess evaluation team/ study health psychologist. If the researchers rate the BCTs within a 
section of the training the same, agreement will be registered. Where one researcher verifies 
a BCT and the other does not, disagreement will be registered.  
 
Assessing client engagement in pharmacies using simulated clients 
Actors will visit each pharmacy and present at the counter with different smoking related sce-
narios which have been designed to present an opportunity for the pharmacy staff to engage 
the potential client with the smoking cessation service. Details on the actors’ training and the 
specific scenarios used for this process and how the actors rate client engagement are out-
lined in a previously published paper [3]. In brief, after completing their smoking related sce-
nario with a member of staff at the pharmacy counter, the simulated client will rate the inter-
action, providing a subjective assessment of skills delivery. They will also make a note of any 
visible NHS stop smoking service or STOP Trial promotional materials e.g. STOP badges, 
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desktop calendars. Each actor will complete this assessment using a checklist after each 
pharmacy visit which has the option of adding brief notes [3]. All actors will receive training in 
this mystery shopper approach by the study team. The data collected will be analysed using 
descriptive statistics.  
 
Audio-recording of adviser-smoker consultations  
Over the trial duration, the study team will ask stop smoking advisers from participating phar-
macies in the intervention arm to record one or two of their consultations with consenting 
smokers who have joined their stop smoking service. These recordings will be used to assess 
enactment and retention of behaviour change skills from advisers. Advisers who agree to do 
this will be given an encrypted audio recorder to use for this purpose. The data collected will 
undergo Roter interaction analysis which is a method widely used to code medical interactions 
worldwide [15].  The Roter interaction analysis system (RIAS) emerged in the late 90s when 
research studies looking at doctor–patient communication grew markedly. Effective commu-
nication between providers and patients is very important to the provision of safe and high-
quality healthcare.  Failures in the communication process can have significant implications 
for patients’ experience, negatively affecting patient satisfaction, adherence, resource utilisa-
tion, and health outcomes [16]. RIAS is based on social exchange theories and linguistic-
based techniques of communication analysis, with a coding framework based on the ‘’three 
function model” of medical interviewing [15]. The coding is performed directly from the audio 
recording without transcription, and data are directly entered into RIAS software. The coders 
assign each word (or complete thought) spoken by the healthcare provider or patient to mu-
tually exclusive and exhaustive categories. These categories can then be combined to reflect 
four larger functional groupings, namely data gathering, patient education and counselling, 
building a relationship, and activating and partnering. For example, in the context of STOP, if 
coders heard open ended questions in a consultation recording, they would categorise this to 
‘task focused communication’, where the adviser is ‘gathering data’ to understand the 
smoker’s problems [16]. Overall, RIAS offers a practical, functional, flexible, and methodolog-
ically rigorous approach for reliably analysing patient and provider interactions in a range of 
contexts [15]. 
 
Pharmacy staff and service user interviews  
To assess acceptability of the STOP intervention, we will conduct interviews with a purposive 
sample of pharmacy staff from participating pharmacies in the intervention arm only and ser-
vice users who provided their consent during the STOP trial to be subsequently approached 
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at 6 months about their smoking status [1]. We will put emphasis on capturing regional varia-
tion so we will purposefully try to get interview participants from all three recruitment sites in 
case there are differences that impact on service delivery or service user experience [17]. The 
STOP Trial recruitment targets are 165 staff and 1200 service users [1]. From this potential 
participant pool, we feel interviewing samples of approximately 10 staff and 25 service users 
will be sufficient to reach data saturation, considering the homogeneity of the population in 
each group [18].  Consenting staff will be approached 5 months after training completion to 
ask if they are willing to participate in a recorded interview. Face-to-face and telephone inter-
views will be conducted depending on respondents’ location. Service users will be approached 
during their 6 month follow up, where long term smoking abstinence is assessed. After com-
pleting their 6 month follow up questionnaire, the STOP researcher will ask the service user if 
they would be willing to participate in a recorded interview to give more detail about their ex-
perience of using their local pharmacy’s NHS stop smoking service.  These interviews will also 
be conducted by telephone or face to face, whatever is more convenient for the service user. 
All the interviews will be conducted by members of the STOP team who were not involved in 
delivery of the STOP intervention training. The interview questions will be guided by semi-
structured topic guides (see table 3). 
 
Booster visit Field notes  
After a pharmacy receives STOP intervention training and has been visited by a simulated 
client (approximately 3 months), the STOP training facilitator will visit the pharmacy to conduct 
a booster visit. During this visit, the facilitator will meet with the lead stop smoking adviser 
and/or STOP local champion for the pharmacy (self nominated during the STOP Training) to 
discuss the pharmacy’s progress implementing the STOP intervention. This will include gaug-
ing presence and usefulness of the STOP promotional materials. The facilitator will also give 
the pharmacy feedback on their simulated client results. Field notes of interactions from these 
visits will be captured using a STOP Booster Visit Checklist (Figure 3). These field notes will 
be later analysed to give insights on the extent to which the target population (pharmacy staff) 
are participating in the intervention. 
 
Qualitative Analysis  
Interviews and adviser-smoker consultations will be digitally recorded, subject to permission 
of each participant, and transcribed verbatim by a Queen Mary approved transcription service 
in line with data management standard operating procedures. The recordings will be stored in 
a secure virtual environment maintained by our host Centre and will be accessed by author-
ised study researchers for analysis. Thematic analysis facilitated by the software package 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted March 21, 2020. .https://doi.org/10.1101/2020.03.17.20037499doi: medRxiv preprint 
NVivo [19] will be used for analysis of the qualitative data. Researcher bias will be minimised 
through regular crosschecking of data and findings by the members of research team. Anon-
ymised quotations will be used where possible as exemplars of key points in the writing up of 
these data. Themes emerging from qualitative data will also be discussed and refined by the 
Process Evaluation Team. To ensure reliability and validity, each team member will code a 
sample (1-2 transcripts) that have already been coded by another member of the team for 
subsequent reviewing and reflection as a group on emerging themes. 
 
Quantitative Analysis  
Quantitative data will be analysed using the statistical package PASW Statistics [20]. Descrip-
tive statistics will be generated and comparisons made between intervention and control phar-
macies from the mystery shopper data. Regional comparisons will also be examined. 
For the training audio-recording data, the first author will summarise total ratings of the pre-
classified BCTs. Observed adherence will be expressed as the number of BCTs applied by 
the facilitator, divided by the number of BCTs specified in the training manual.   
The data analysis for the process evaluation data will be an ongoing process and will occur in 
parallel but independently of the main study, before the two data sets are combined [5]. To 
ensure good quality data, the process evaluation team will share and review extracted data 
results at regular intervals.  
 
Ethics and dissemination 
The STOP trial and its process evaluation has ethical approval from the UK National Research 
Ethics Service (NHS REC reference 17/SC/0067) given on 3 April 2017. Findings will be dis-
seminated via peer reviewed journals and conferences. Considering the limited research and 
training culture observed in the community pharmacy setting, we also plan to deliver work-
shops or seminars on methodology of the process evaluation to relevant stakeholders and 
service commissioning. Brief reports will be shared with participants, mystery shoppers and 
funder. 
 
Discussion  
This paper describes the design and methodology for the planned process evaluation of the 
STOP trial using a mixed methods approach. The process evaluation protocol and results will 
contribute to the continuously developing literature around the conduct of process evaluation 
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for complex health interventions and the value they add to health services research and de-
livery. The process evaluation protocol follows recommendations intended to help standardise 
the design and reporting of process evaluation. This will hopefully enable future trials to con-
duct similar evaluations of their work, resulting in synthesis of stronger evidence base regard-
ing effective interventions.   
 
Trial status 
The current approved STOP Trial protocol is version 4.0 dated 21.03.17. Recruitment to the 
trial began on 3rd April 2017. Data collection for the process evaluation is still ongoing; to be 
completed in April 2020. 
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Table 1: Summary of STOP Trial process data collection 
Outcomes Description of data collection process  Time of collection Data source  
1) Study recruitment and 
retention process  
(implementation concerns) 
(i) Completed site initiation visit training 
logs from intervention pharmacies  
(ii) Reasons for withdrawal in intervention 
arms e.g. no longer delivering service 
(iii) number of completed booster visits and 
analysis of field notes  
From recruitment 
and over the course 
of the study as it 
happens 
Recorded by 
study team 
2) Intervention attendance 
and completion rates. Rea-
sons for non-attendance 
and dropout. 
(i) Estimate STOP training intervention (a) 
attendance i.e. Number of staff who attended 
training/number assigned/who agreed to re-
ceive the intervention and (b) dropout rates 
among pharmacy staff i.e. Number who 
dropped out of training/number attended  
 (ii) Record reasons for non-attendance and 
non-completion 
Following attend-
ance in sessions 
Recorded by 
study team 
3) Acceptability of inter-
vention training and deliv-
ery in practice. 
Post training feedback forms  
 
Questionnaire using previously developed 
Likert scale 
 
Pharmacy staff interviews  
After training      
session 
At 5 months post 
written consent date. 
 
6-9 weeks post 
training 
Directly 
from inter-
vention 
pharmacy 
staff 
4) Fidelity assessment at 
the pharmacy counter  
Assessment of delivery of skills in practice at 
the pharmacy counter (in all 60 pharmacies) 
around engagement of service users into the 
NHS SSP via simulated client using checklist 
developed for study. 
4-6 weeks post train-
ing 
Directly 
from phar-
macy staff. 
5) Fidelity assessment in 
pharmacy consultation 
room.  
Assessment of skills (from 33% of 30 inter-
vention pharmacies, n=10) around retention 
and quit success via audio-recording consul-
tations. 
4-6 weeks post train-
ing 
Directly 
from inter-
vention 
pharmacy 
staff 
6) Fidelity assessment in 
training sessions 
Assessment of facilitator adherence to behav-
iour change techniques outlined in the inter-
vention training manual via audio-recordings 
of training sessions  
Intervention training 
sessions  
Recorded by 
study team 
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7) Views and experiences 
about the STOP training 
and its delivery in practice. 
Interview data about views of the STOP 
training intervention and delivery of learnt 
skills in practice, reasons for non-attendance 
and non-completion. 
6-9 weeks post train-
ing 
Directly 
from inter-
vention 
pharmacy 
staff 
8) Views and experiences 
about the NHS SSP with a 
focus on engagement and 
retention, reasons for com-
pletion and non-comple-
tion of the NHS SSP. 
Interview data about experience of the NHS 
SPP focusing on engagement ad retention 
into the programme, reasons for non-comple-
tion of the programme.  
At 6 months follow 
up  
Directly 
from service 
users 
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Table 2: STOP Trial Intervention Training Content 
 
Training Content 
 
Behaviour change techniques 
Introduction 
General orientation to STOP programme and aims of training. 
Emphasise backing from local and national opinion leaders and organisations (e.g. Local Pharmaceutical Com-
mittee, Royal Pharmaceutical Society, local CCGs and public health commissioners. 
Discussion of impact of advisor behaviour on client stop smoking outcomes so far and health benefits to patients 
from stopping smoking. 
Delivered in mixed groups of pharmacists and other pharmacy workers to promote cohesive working practices 
within the individual pharmacies.   
 
5.1 Information on health 
consequences of behaviour 
9.1 Credible source 
10.6 Nonspecific incentive 
15.1 Verbal persuasion about 
capability  
Why are we here?  
Smoking facts and exploration of motivation for helping smokers to quit with feedback.  
Discuss focus on pharmacy setting, emphasising the non-medication related, professional and public health 
aspects of the pharmacy role.  
Does engaging and supporting smokers’ quit fit with role identity, any barriers? Encourage self-perception as 
supporters and providers of health, how one will feel if help smokers quit.  
Emphasise the non-medication related, professional and public health aspects of the pharmacy role, promote a 
person-centred rather than product-centred ethos and foster a strong sense of professionalism 
 
5.6 Information about emotional consequences 
9.2 Pros and cons 
6.3 Information about others approval 
13.1 Identification of self as a role model 
15.3 Focus on past success 
 
Engaging Clients  
Celebrate successful cases.  
Group exercise and discussion on difficult and easy clients to engage – potential problems and solutions.   
Addressing pharmacy workers beliefs and attitudes e.g. prejudgement of success or failure. 
 
 
1.2 Problem solving, 
8.1 Behavioural practice and rehearsal 
9.2 Pros and cons 
13.3 Incompatible beliefs 
15.3 Focus on past success 
Patient-centred approach: Building rapport & shift of focus  
Introduction of patient-centred approach using group exercise. Group identification and discussion of the im-
portance of utilising basic communication skills (rapport, active listening, questioning).     
Review how patient-centred approach can be incorporated into smoking cessation interactions for better patient 
outcomes  
Role-play demonstration with senior pharmacist, participant practice.  How to maximise opportunity with en-
vironmental resources e.g. staff wearing STOP badges to prompt client interaction, STOP posters. 
Emphasise predictable improved results, simplicity of use and benefits over usual practice.  
 
4.1 Instruction on performance of behaviour,   
6.1 Demonstration of behaviour 
7.1 Prompts and cues 
8.1 Behavioural practice and rehearsal 
8.2 Behaviour substitution 
8.6 Generalisation of target behaviour  
9.2 Pros and cons 
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 9.3 Comparative imagining of future outcomes 
NCSCT Knowledge Review  
Review group’s NCSCT knowledge with a quiz and general feedback   
 
1.6 Discrepancy between current behaviour and 
goal 
9.1 Credible source  
Pharmacy role in smoking cessation  
Discuss individual pharmacies’ NHS Stop Smoking service structure and purpose of smoking treatment, with 
experienced advisers sharing current and best practice. Group reflection on challenges  
 
 
1.7 Review outcome goal(s) 
 
Behaviour change as smoking cessation treatment 
Emphasise behaviour change support as part of smoking cessation treatment within NHS SSS.  
Information on how to assess someone’s readiness to quit smoking using 1-10 scales.  
 
4.1 Instruction how to perform behaviour 
8.1 Behavioural practice and rehearsal 
Behaviour change using patient-centred approach in Smoking Cessation Treatment: Double Whammy 
Brainstorm factors that influence behaviour change i.e. role of beliefs, capability, opportunity alongside 
knowledge.  
How to elicit individuals’ motivations, barriers and potential strategies to change behaviour versus offering 
solutions.  Using ‘What else questions’.  
Understanding the ‘non-smoker identity’ and how to communicate to client. 
Demonstration & Role play. 
What makes this client centred approach difficult - advantages, disadvantages, barriers and strategies to aid 
implementation? 
 
 
1.2 Problem Solving  
4.1 Instruction on how to perform behaviour 
6.1 Demonstration of behaviour 
8.1 Behavioural practice and rehearsal 
9.2 Pros and Cons 
 
Client engagement in pharmacy: Planning a Quit & Dealing with Lapses 
Discuss planning a quit and how to help people make a specific plan using a SMART approach. Go over ways 
to discuss with lapses and provide supportive praise.  
 
Discussion of how to talk about willpower and the role of the open door.  
 
Watch and reflect on video of strong and weak consultations of quit planning.   
 
Demonstration & Role play 
 
 
1.1 Goal setting (behaviour) 
1.2 Problem solving  
3.1 Social support (unspecified) 
4.1 Instruction on how to perform behaviour 
6.1 Demonstration of behaviour  
8.1 Behavioural practice and rehearsal 
Client engagement in pharmacy: Goal Setting & Making a Commitment  
Facilitate goal setting and elicit verbal commitment from participants. 
Demonstration (via video). 
Practice cohesive working amongst trainees through role play using multiple scenarios and observer feedback. 
 
1.1 Goal Setting (behaviour) 
1.9 Commitment 
3.1 Social support (unspecified) 
8.1 Behavioural practice and rehearsal 
15.1 Verbal persuasion about capability 
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Table 3: Summary of topic guides for pharmacy staff and service user interviews  
 
Topic guide for interviews with pharmacy staff 
§ Barriers to training intervention - non-attendance or dropout 
§ Facilitators to training intervention attendance  
§ Acceptability of training (probe length, structure, content, timing etc.) 
§ Feasibility of delivering intervention in practice (probe things that worked/didn’t work) 
§ Barriers to implementing the intervention in practice 
§ Pharmacy staff view of client perception of intervention received  
Topic guide for interviews with smoker service users 
§ Overall view of programme 
§ How they were approached to take part in programme / how did they feel about it 
§ Reasons for completing/ dropping out of the programme 
§ How were the sessions delivered – what was covered 
§ What bits they found most/least useful 
§ Were there things that could have been improved in delivery of programme 
§ Views on pharmacy environment 
 
Implementing STOP  
Review how to implement STOP in practice (i.e. prompts and WhatsApp support) by facilitating discussion of 
implementation plans alongside facilitators or barriers with pharmacy team  
Highlight use of local champions and prompts/cues including the Double Whammy (a desk calendar with visual 
cues and example questions to ask) to prompt client interaction. 
Highlight ongoing social support via WhatsApp 
Promote adaptation of non-core elements of the intervention through a prompted pharmacy team meeting to 
discuss implementation of the intervention according to the needs of each individual pharmacy e.g. appointment 
of individual champions, monthly ‘STOP’ smoking days 
 
4.1 Instruction on how to perform behaviour 
1.2 Problem Solving 
7.1 Prompts and Cues 
3.2 Social support (practical)  
1.4 Action planning 
10.1 Material incentive (behaviour) 
End of Session  
Participants provided with a certificate for attending the training linked to CPD (endorsed by RPS) 
Provide financial reward for completing intervention training 
 
10.2 Material reward  
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Addressing 
pharmacy workers 
knowledge,  skills 
and attitudes will 
make them more 
effective at 
recruiting smokers 
and helping them to 
quit
Increased self efficacy  
will make workers 
more likely to engage 
with clients and to 
work with them more 
effectively
Increased intrinsic and 
extrinsic motivation and 
more valued self identity 
will lead to more effective 
clinical practice
Assumptions Inputs              Activities                  Outputs                               Outcomes           Impact
Increased total 
number of people 
who have stopped 
smoking with the 
help of the NHS 
Community 
Pharmacy Smoking 
Cessation Service 
(comparison with 
historical 
pharmacy data) 
Increased 
throughput in 
the NHS Smoking 
Cessation service 
(no. of smokers 
entering service)
Improved quit 
rates
(proportion of 
quits at 4 weeks 
& 6 months) 
Better smoker 
engagement, recruitment 
and retention 
(no. entering service, 
dropout rate, NCSCT 
questionnaire, interviews, 
simulated client report)
More client focused 
counselling and improved 
rapport of counter staff 
(simulated client report, 
interviews) 
Improved behaviour 
change skills 
(simulated client report, 
recorded consultation 
analysis)
Study materials 
(Double Whammy 
desk calendar, 
pens, posters and  
badges)
Financial 
incentive 
(no. of payments 
made to attend 
training, service 
support costs)
Continuing 
professional 
development 
certificates 
(no. distributed)
Training sessions
•Health consequences of 
smoking cessation
•how to perform health 
behaviour change  (modelling, 
role play)
•adapting STOP Intervention 
to local circumstances – fuzzy 
boundaries
•finding local champions
(analysis of audio recorded 
sessions)
Belief that the STOP 
intervention is simple, 
more effective than 
usual practice and fits 
with ‘pharmacy’ ethos 
makes implementation 
more likely
Modelling on 
experienced advisors 
improves skills
Improved self 
regulation leads to 
better judgements on 
readiness to quit, goal 
setting and problem 
solving, action planning
Fidelity testing
•Audio recording of training 
sessions
•simulated client report on 
display of prompts and client 
engagement  
Smokers 
(smoking 
prevalence 
around 
pharmacies)
Pharmacy workers 
(proportion 
recruited)
Staff: 
health 
psychologist, 
pharmacist tutor, 
actors
WhatsApp 
for ongoing support and 
general communication
Prompts and cues are 
displayed in the pharmacy 
(simulated client report on 
visibility, booster visit field 
notes, interviews)
Timely provision of certificates 
and payments (attendance and 
expenses logs)
Easily accessible 
venues and times 
for training
Pharmacy workers have 
increased self efficacy in 
providing  smoking 
cessation service 
(change in SE scores on 
staff questionnaire, 
interviews) 
Booster visits
•Performance feedback 
•Ongoing support
•Implementation concerns  
follow up 
(field notes by STOP team)
Site initiation visits
•Emphasise pharmacy role in 
health promotion, explain 
simplicity of intervention
•Address concerns about 
implementation
(no. of staff recorded on 
training logs)
Solicit backing of opinion 
leaders
•Service commissioners and 
professional bodies (CCGs, 
LPCs, RPS)
High acceptability of STOP 
Intervention
(% staff trained, training 
attendance rates, staff 
questionnaire, interviews, 
booster visit field notes)  
Figure 1: STOP Trial Logic model  
Increased total 
number of peo-
ple who have 
stopped smoking 
with the help of 
the NHS Com-
munity Pharmacy 
Smoking Cessa-
tion Service 
(comparison with 
historical phar-
macy data)  
Increased 
throughput in 
the NHS Smok-
ing Cessation 
service (no. of 
smokers enter-
ing service) 
Improved quit 
rates 
(proportion of 
quits at 4 
weeks & 6 
months)  
Better smoker engage-
ment, recruitment and re-
tention  
(no. entering service, 
dropout rate, NCSCT 
questionnaire, inter-
views, simulated client 
report) 
Prompts and cues are 
displayed in the phar-
macy (simulated client 
report on visibility, 
booster visit field notes, 
interviews) 
Pharmacy workers have 
increased self efficacy in 
providing  smoking ces-
sation service  
(change in SE scores on 
staff questionnaire, inter-
views)  
High acceptability of 
STOP Intervention 
(% staff trained, training 
attendance rates, staff 
questionnaire, inter-
views, booster visit field 
notes)   
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Figure 2: Key MRC process evaluation components, associated STOP process evaluation theoretical assumptions and data 
 
Key components of process evalua-
tion a 
     STOP theoretical assumptions b     Process data collected c 
Implementation process STOP Team clearly explain the trial, intervention 
and pharmacy role, while addressing  
implementation concerns 
Completed training logs from site initiation visits; availability and 
accessibility of training venues; dissemination of intervention  
materials from mystery shopper data 
 Fidelity of delivery  Facilitators go through key elements of training 
content to facilitate pharmacy staff's knowledge, 
skills and attitudes to enable behaviour change 
Analysis of intervention training session audio-recordings 
Adaptations Facilitators adapt intervention based on local 
pharmacy needs e.g. region with small stagnant 
community, free prescriptions in Wales  
Analysis of intervention training sessions audio-recordings;  
number of onsite (condensed) training 
Fidelity of skills performance/ adop-
tion of intervention  
trained staff will have better smoker engagement 
behaviour  
Actors’ fidelity assessments; stop smoking adviser-smoker  
consultation recordings 
Dose how much intervention training was delivered 
and received 
number of intervention pharmacies and consented staff trained; 
number of completed booster visits  
Reach  high proportion of staff exposed to intervention 
activities increases uptake 
intervention arm pharmacy staff turnover data; pharmacy  
withdrawals; pharmacy staff dropout rates 
Contextual (external) factors unintended factors in the community pharmacy 
environment may hinder or buffer implementa-
tion of STOP INT  
Staff and service user interviews; booster visits field notes;  
recruitment logs on changes to service provider; payment structure 
data from commissioners; pharmacy staff turnover data; Smoking 
and e-cigarettes prevalence data; regional differences 
   a from MRC guidance (Moore et al, 2015) b based on STOP Logic model c outlined in the STOP Trial protocol (Sohanpal et al, 2019)  
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Figure 3: STOP booster visit checklist 
 
 
 
Discuss implementation of STOP Intervention training in pharmacy 
1. What impact has the STOP training had on trained pharmacy staff? 
 
 
 
2. What impact has the STOP training had on your pharmacy’s approach to the NHS stop smoking service? 
 
 
 
3.    How useful were the STOP environmental materials e.g. desk calendar, badges? 
 
 
 
  
Give pharmacy brief feedback on fidelity assessment results 
Summary of fidelity results 
• Visibility of NHS stop smoking service leaflets 
  
• Visibility of STOP study posters / badges  
  
• Rates of client engagement  
  
• Specific good points: 
  
Do you (pharmacy staff) have any comments regarding these fidelity results? 
  
Collect Self-efficacy questionnaires from staff  
Number of questionnaires collected? 
  
Number outstanding?  
  
Any ongoing action plans  
  
 
Pharmacy ID: 
Staff ID: 
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